Protocol Ledger

NCT05879718 · Phase II · TERMINATED

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Interventional Phase II clinical trial protocol NCT05879718 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-07 Enrollment: 8 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05879718
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05879718
Protocol FieldVerified Registry Value
NCT IdentifierNCT05879718
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment8 participants (ACTUAL)
Registered Start Date2023-07-07
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05879718
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI